Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q08830
UPID:
FGL1_HUMAN
Alternative names:
HP-041; Hepassocin; Hepatocyte-derived fibrinogen-related protein 1; Liver fibrinogen-related protein 1
Alternative UPACC:
Q08830; A6NKU4; Q4PJH9; Q53YF1; Q8NG32; Q96KW6; Q96QM6
Background:
Fibrinogen-like protein 1, also known as Hepassocin, plays a pivotal role in immune regulation and hepatocyte growth. It acts as a major ligand of LAG3, inhibiting antigen-specific T-cell activation independently from MHC class II. This protein is also involved in the promotion of hepatocyte growth, showcasing its multifunctional nature.
Therapeutic significance:
Understanding the role of Fibrinogen-like protein 1 could open doors to potential therapeutic strategies. Its unique ability to suppress immune responses and promote hepatocyte growth positions it as a key target for drug discovery in immune-related disorders and liver diseases.